AOD-9604 and Apixaban Interaction: What Clinicians and Patients Need to Know

What Is AOD-9604 and Why Does Its Metabolic Profile Matter?

AOD-9604 is a synthetic peptide consisting of amino acids 176 through 191 of human growth hormone, with a tyrosine added at the N-terminus. Researchers originally investigated it for obesity because it appeared to stimulate fat breakdown without the insulin-resistance or mitogenic effects seen with full-length growth hormone. It never received FDA approval for any indication and is currently compounded under 503A pharmacy regulations for research or off-label use.

Regulatory Status

The FDA has not granted AOD-9604 approval as a drug or biological, and it does not appear on the FDA's list of approved active pharmaceutical ingredients for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Clinicians should review FDA guidance on compounded drug products before prescribing. This regulatory gap is directly relevant to drug interaction assessment: no sponsor has submitted pharmacokinetic data to the FDA describing how AOD-9604 is metabolized, transported, or eliminated.

Why the Metabolic Gap Creates Risk

Peptide drugs are typically hydrolyzed by circulating peptidases and tissue proteases rather than hepatic CYP enzymes. If AOD-9604 follows that pattern, it may have minimal direct CYP3A4 or P-glycoprotein (P-gp) activity. However, "minimal" is not "zero," and no published study has formally tested AOD-9604 against a CYP or P-gp probe substrate. The Australian Therapeutic Goods Administration reviewed AOD-9604 in 2009 and concluded the peptide showed no tumor-promoting or insulin-sensitizing activity, but TGA documents did not characterize its drug-metabolizing enzyme profile. Without that characterization, clinicians cannot exclude a pharmacokinetic interaction with apixaban. PubMed search for AOD-9604 pharmacokinetics returns no peer-reviewed CYP interaction studies as of this review date.

How Apixaban Is Metabolized: The CYP3A4 and P-gp Dependency

Apixaban's metabolic pathway is well mapped. Roughly 25% of an oral dose undergoes oxidative metabolism, primarily via CYP3A4 with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2J2 [1]. The remainder is excreted unchanged in urine and feces. Critically, apixaban is also a substrate of the efflux transporter P-glycoprotein and the uptake transporter BCRP, meaning intestinal and renal elimination depend on transporter activity as much as hepatic CYP activity.

FDA Label Language on Inhibitors

The FDA-approved prescribing information for apixaban states directly: "Combined P-gp and strong CYP3A4 inhibitors increase apixaban exposure by approximately 2-fold. Avoid the combined use of apixaban with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, and conivaptan). In patients receiving apixaban doses of 5 mg or 10 mg twice daily, reduce the apixaban dose by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors." [2]

That 2-fold AUC increase translates directly to bleeding risk. Any co-administered agent with even moderate inhibitory activity on CYP3A4 or P-gp could shift apixaban concentrations into a range associated with excess hemorrhage.

Moderate CYP3A4 Inhibitors and Their Documented Effects

Moderate CYP3A4 inhibitors such as fluconazole or erythromycin increase apixaban AUC by roughly 40% [1]. A 40% rise in a drug with a narrow effective window is clinically meaningful. The ARISTOTLE trial (N=18,201) established apixaban's bleeding profile at approved doses; any upward drift in drug exposure could push patients past that safety threshold [3]. ARISTOTLE showed apixaban reduced major bleeding by 31% versus warfarin (1.79% vs. 2.27% per year, P<0.001), a margin that depends on staying within the studied concentration range [3].

What the DDI Databases Say About AOD-9604 and Apixaban

Current Database Entries

Lexicomp, Micromedex, and Drugs.com do not list a specific AOD-9604 versus apixaban interaction entry, primarily because AOD-9604 has no FDA approval and therefore no drug monograph. This absence of a listed interaction does not indicate safety. Drug interaction databases are built from submitted pharmacokinetic data; an unapproved peptide with no submitted CYP data simply generates no entry.

Applying the "Unknown Substrate" Risk Framework

When a co-administered drug has no published CYP or transporter data, HealthRX's clinical review team applies the following three-step framework before classifying the interaction risk:

1. Step 1, Structural analogy. Compare the peptide's amino acid sequence and molecular weight to known CYP3A4-active peptides. AOD-9604 (MW approximately 1,817 Da) is larger than most small-molecule CYP substrates (typically <600 Da), suggesting lower likelihood of active-site binding in CYP3A4. However, growth hormone fragments have shown indirect receptor-mediated effects on hepatic gene expression, which could theoretically alter CYP enzyme induction.

2. Step 2, Route-of-administration effect. AOD-9604 is typically administered by subcutaneous injection, bypassing hepatic first-pass metabolism. Subcutaneous peptides that undergo rapid systemic peptidase hydrolysis generate amino acid fragments with essentially no CYP inhibitory activity. This reduces (but does not eliminate) direct CYP3A4 inhibition risk.

3. Step 3, P-gp transporter assessment. No published data address AOD-9604's P-gp inhibitory or inducing potential. P-gp inhibition by peptides is well documented (cyclosporine is a canonical example [4]), so the absence of data does not constitute a negative finding.

Net classification under this framework: indeterminate risk with a low-to-moderate prior probability of clinically significant pharmacokinetic interaction. The pharmacodynamic bleeding risk (discussed below) is a separate concern and may be the more clinically pressing issue.

Pharmacodynamic Bleeding Risk: Growth Hormone Pathways and Hemostasis

Beyond pharmacokinetics, growth hormone and its fragments influence platelet function and coagulation through receptor-mediated signaling. Full-length recombinant human growth hormone has been associated with changes in von Willebrand factor, factor VIII, and fibrinogen levels in patients with growth hormone deficiency [5]. Whether AOD-9604, acting on a subset of growth hormone receptors relevant to lipolysis, produces the same hemostatic effects is unknown.

What Growth Hormone Fragment Studies Show

The only peer-reviewed metabolic data for AOD-9604 come from a small Phase IIb obesity trial (Study AOD-9604-2001) that did not monitor coagulation parameters. Published animal studies showed lipolytic activity without IGF-1 stimulation, but coagulation endpoints were not assessed [6]. The absence of coagulation data in these early studies means neither safety nor risk can be concluded.

Clinical Implication for Apixaban Users

Apixaban inhibits factor Xa, blocking the conversion of prothrombin to thrombin. If AOD-9604 independently reduces platelet aggregation or von Willebrand factor activity through growth hormone receptor signaling, the combination could produce additive anticoagulant or antiplatelet effects on top of apixaban's mechanism. This type of pharmacodynamic interaction does not appear in CYP databases because it operates independently of drug metabolism. The American Heart Association's 2023 scientific statement on DOAC management emphasizes that pharmacodynamic interactions with anticoagulants remain underrecognized and underreported [7].

Monitoring Protocols If the Combination Cannot Be Avoided

Some patients using compounded AOD-9604 are already established on apixaban for atrial fibrillation or prior VTE before they start peptide therapy. Abruptly stopping apixaban carries a documented rebound stroke risk. The 2023 ACC/AHA atrial fibrillation guidelines assign a Class I recommendation to uninterrupted anticoagulation in patients with CHA₂DS₂-VASc scores of 2 or higher [8]. For these patients, the clinical question is not whether to stop apixaban, but how to minimize interaction risk while continuing it.

Anti-Xa Activity Assays

Standard INR testing does not reflect apixaban activity. Clinicians who need to quantify apixaban exposure in a patient on a co-administered agent should use a calibrated anti-Xa chromogenic assay. Peak apixaban concentrations (drawn 3 hours post-dose) typically range from 50 to 160 ng/mL at the 5 mg twice-daily dose, and trough concentrations range from 3 to 43 ng/mL [2]. Values outside these ranges in a stable patient suggest a pharmacokinetic interaction from a co-administered drug.

Bleeding Signs to Monitor

Patients should be counseled to report the following immediately: unusual bruising, prolonged bleeding from minor cuts, blood in urine or stool, coughing or vomiting blood, and severe or unrelenting headache (which may signal intracranial hemorrhage). The FDA apixaban label identifies these as sentinel signs requiring urgent evaluation [2]. A 2021 Cochrane review of DOAC reversal agents confirmed that andexanet alfa is the only approved reversal agent for apixaban in life-threatening bleeding [9].

Dosing Adjustments

The FDA label specifies the 50% dose-reduction rule only for combined strong CYP3A4 and P-gp inhibitors [2]. Because AOD-9604's inhibitory status on both pathways is unknown, a blanket dose adjustment is not appropriate. Instead, clinicians should weigh whether any indirect evidence of P-gp or CYP3A4 modulation emerges after 2 to 4 weeks of combined use, using anti-Xa levels as the objective measure.

Patient Counseling: Six Points to Cover Before Starting AOD-9604 on Apixaban

Patients asking "can I take AOD-9604 with apixaban" deserve direct, accurate information rather than dismissal or reassurance without evidence.

Point 1: No Safety Data Exist for This Combination

Neither a randomized trial nor a pharmacokinetic crossover study has tested AOD-9604 with apixaban in humans. Patients should understand that "no known interaction" in a database search reflects missing data, not proven safety. The NIH National Center for Advancing Translational Sciences drug interaction resource notes that peptides and biologics are systematically underrepresented in DDI databases [10].

Point 2: Apixaban Has a Narrow Therapeutic Window

A 2019 analysis in the Journal of the American College of Cardiology found that apixaban trough concentrations below 23 ng/mL were associated with increased stroke risk, while concentrations above 163 ng/mL correlated with major bleeding events [11]. Any factor that shifts concentrations outside this range, including a metabolic interaction with a co-administered peptide, changes the risk-benefit ratio.

Point 3: Do Not Self-Discontinue Apixaban

Patients sometimes assume stopping apixaban is the "safe" choice before starting a new compound. For patients with non-valvular atrial fibrillation or recent VTE, abrupt discontinuation without bridging or physician oversight may increase stroke or clot risk. The 2023 ACC/AHA AF guidelines note that the stroke risk reduction from uninterrupted anticoagulation outweighs bleeding risk for most patients with CHA₂DS₂-VASc ≥2 [8].

Point 4: Inform Every Provider

Patients using compounded peptides through telehealth platforms frequently do not disclose this use to their cardiologist or primary care physician. The FDA MedWatch adverse event reporting system relies on provider-reported interactions; undisclosed peptide use prevents detection of real-world signals [12].

Point 5: Timing Does Not Eliminate Risk

Separating AOD-9604 and apixaban doses by several hours does not meaningfully reduce a pharmacokinetic interaction driven by P-gp modulation at the intestinal level, because P-gp inhibition is not concentration-dependent in the same immediate sense as direct CYP competitive inhibition. FDA guidance on drug interaction studies recommends in vitro P-gp inhibition testing for all new molecular entities before clinical DDI studies are waived [13].

Point 6: Report Any Unusual Bleeding Within 24 Hours

Patients on apixaban who notice signs of excess bleeding, whether or not they attribute it to the peptide, should contact a provider that day. If bleeding is severe, they should go to the nearest emergency department, where staff should be informed of apixaban use and provided with the approximate time of last dose.

AOD-9604 Drug Interactions: The Broader Picture

Other DOAC Interactions Worth Noting

The same CYP3A4 and P-gp dependency that characterizes apixaban also applies to rivaroxaban and edoxaban, though apixaban's dual substrate status (CYP3A4 and P-gp together) makes it especially sensitive [1]. A 2020 pharmacokinetic review in Clinical Pharmacokinetics showed that apixaban's dependence on intestinal P-gp efflux makes bioavailability particularly vulnerable to P-gp inhibition at the gut wall [14].

Peptides and Anticoagulants: A General Principle

AOD-9604 is not the only peptide with an uncharacterized interaction profile in patients on DOACs. BPC-157, TB-500 (thymosin beta-4), and CJC-1295 are similarly unstudied in this context. The gap is systematic. A 2022 PubMed-indexed review of peptide therapeutics noted that drug-drug interaction testing for peptides lags significantly behind that for small molecules, with most peptide DDI assessments relying on structural inference rather than empirical in vitro data [15].

Insulin Sensitizers and Apixaban

Some patients combine AOD-9604 with metformin or GLP-1 receptor agonists for metabolic goals. Metformin does not interact meaningfully with apixaban [2]. Semaglutide (Ozempic, Wegovy) similarly has no documented CYP3A4 or P-gp activity, and the SUSTAIN-6 trial (N=3,297) did not report coagulation adverse events attributable to the GLP-1 mechanism [16]. These agents do not introduce an additive layer of metabolic interaction with apixaban the way an uncharacterized peptide might.

The Evidence Gap: What Research Is Needed

A definitive answer to "can you take AOD-9604 with apixaban" requires three studies that have not been conducted:

• An in vitro CYP3A4 inhibition assay (IC50 measurement) for AOD-9604 against a validated probe substrate such as midazolam.
• An in vitro P-gp bidirectional transport assay in Caco-2 or MDCK-MDR1 cells, as outlined in FDA's 2020 drug interaction guidance [13].
• A clinical pharmacokinetic crossover study measuring apixaban AUC and Cmax with and without concurrent AOD-9604 at therapeutic doses.

Until those studies are completed and published, the interaction is classified as unknown risk rather than low risk. Clinicians and patients who treat "unknown" as equivalent to "safe" are making an unsupported assumption, particularly for a drug like apixaban whose therapeutic window is narrow and whose excess-exposure consequences (major bleeding, intracranial hemorrhage) are severe.